

11th July 2024

Jill Smith
CEO
Australasian Society of Clinical Immunology and Allergy
Suite 29, 117 Old Pittwater Road
Brookvale NSW 2100

Dear Jill,

Information for Healthcare professionals: Update on Alfamino[®] 400g and PBS

We are providing an update on Alfamino[®] and the PBS to support healthcare professionals with patients who require prescriptions for Alfamino[®].

The recipe of Alfamino[®] infant formula was updated in 2023 with the addition of two **Human Milk Oligosaccharides (HMOs) 2'-FL and LNnT**, structurally identical to those HMOs found in breastmilk^{1,2}. Since 1 September 2023, both the newer and older recipe Alfamino[®] products have been available on the PBS.

From **1 August 2024**, the older formulation of Alfamino[®] infant formula will be deleted. The updated **Alfamino[®] recipe (with HMOs) will continue to be available on the PBS.**

This means that from 1 August 2024, prescribers should only use the item codes for the updated Alfamino[®] product.

More details on the new recipe and the deletion of the older Alfamino[®] formulation from the PBS are below:

Alfamino[®] 400g with HMOs

The updated Alfamino[®] recipe (with HMOs) introduced in 2023 will continue to be available on the PBS, per item codes below:

13615N	Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides with 2-fucosyllactose and lacto-N-neotetraose powder for oral liquid, Alfamino 400 g
13627F	Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides with 2-fucosyllactose and lacto-N-neotetraose powder for oral liquid, Alfamino 400 g

This Alfamino[®] recipe (with HMOs):

- is the first and only amino acid based infant formula in Australia to contain HMOs; and
- continues to be an amino acid based infant formula, specifically formulated for infants (0-12 months) with severe cow's milk protein allergy, eosinophilic oesophagitis, intestinal malabsorption and/or multiple food intolerances.

The HMOs in the new Alfamino[®] recipe are structurally identical to the HMOs 2'FL and LNnT found in breast milk. Research shows that inclusion of these HMOs in infant formula products supports safe growth in formula-fed babies and that they are well tolerated³⁻⁶

Furthermore, additional studies* show growing evidence that formula-fed infants who consumed infant formula products containing the HMOs 2'FL and LNnT (including those with and without cow's milk protein allergy), have:

- Selective growth of beneficial gut microbiota^{3,5}

- A reduction in infection^{3,6}
- A reduction in infants requiring antibiotic and antipyretic medication over 12 months^{3,6}

Some studies show secondary outcomes^{3,6}

The addition of 2'-Fucosyllactose and Lacto-N-neotetraose in the new Alfamino® recipe is shown on the back of pack only, featuring in both the ingredient list and the nutrition information panel (NIP).

Discontinuation of the older formulation of Alfamino® infant formula

The older formulation of Alfamino® infant formula will be deleted from the PBS on 1 August 2024. There will be a supply only period, which will enable dispensing the product for existing prescriptions but no new prescriptions can be written for the below item numbers as of 1 August 2024.

2900P	Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides powder for oral liquid, Alfamino 400 g
2928D	Amino acid synthetic formula supplemented with long chain polyunsaturated fatty acids and medium chain triglycerides powder for oral liquid, Alfamino 400 g

Expanded access for prescription-holders

We know the importance of PBS-listed nutrition products being accessible when prescribed for your paediatric patients. There are now more ways for prescription-holders to access Nestlé Health Science products - Alfamino® and Alfamino® Junior.

1. Pharmacy Online

For online purchase and nation-wide delivery (prescription holders only), please visit pharmacyonline.com.au. You will be redirected to Pharmacy Online.*

2. Direct supplied pharmacies

Pharmacies that are supplied directly by Nestlé Health Science for prescription holders:

- VIC: Wood Pharmacy, located in Royal Children's Hospital
Address: The Royal Children's Hospital, 50 Flemington Rd, Parkville VIC 3052
Phone: (03) 9345 6500
- NSW: Hospital Foyer Pharmacy, located in Prince of Wales Hospital
Address: Level 0, Randwick Hospitals Campus Centre, Barker Street, Randwick NSW 2031
Phone: (02) 9382 8800
- QLD: Mater Pharmacy Salmon Building South Brisbane
Level 2 Salmon Building, Raymond Terrace, South Brisbane QLD 4101
Phone: (07)-3163 8234

Mater Pharmacy Vulture Street South Brisbane
Level 6 Mater Private Hospital, 301 Vulture Street, South Brisbane QLD 4101
Phone: (07)-3163 1059
- WA: Amcal Pharmacy, Tuart Hill
Address: 3/85 Wanneroo Road, Tuart Hill, WA 6060
Phone: (08) 9349 9611
- SA: National Pharmacies
Phone: 1300 667 676

3. All pharmacies – wholesaler product code.

Available for purchase across all pharmacies nationally who can assist with buying the product in through their wholesale network. Wholesaler product codes (PDE) are provided in the table below:

Wholesaler	Alfamino® Nestle product code: 12534747	Alfamino® Junior Nestle product code: 12487428	Peptamen® Junior Nestle product code: 12191337
Symbion (Contact: 1300 772 000)	764426	738654	171077
API (Contact: 02 8844 2000)	194253	190052	910635
Sigma Healthcare (Contact: 03 9215 9215)	10033298	10031302	10003476

For any further enquiries or support, please contact your Nestlé Health Science account specialist or call Consumer Services team on 1800 671 628.

We thank you for your ongoing support,

Marisa Nastasi



Medical Affairs Specialist

Nestle Health Science

Email: marisa.nastasi@au.nestle.com

Address: 1 Homebush Bay Drive, Rhodes, NSW 2138

ALFAMINO® is an infant formula product for special dietary use and must be used under medical supervision. It is not suitable for general use. ALFAMINO® Junior is a food for special medical purposes specifically formulated for the dietary management of children with multiple food allergies (including cow's milk allergy) and malabsorptive conditions. Must be used under medical supervision.

*Please read Pharmacy Online terms and conditions as Nestlé Health Science is not liable for our partner sites. Subject to availability.

REFERENCES: 1. Glycom A/S Application for the Approval of 2'-O-Fucosyllactose (2'-FL) and Lacto-N-neotetraose (LNnT) Under Standard 1.5.1 (Novel Foods) of the Australia and New Zealand Food Standards Code Appendix IV; 2. FSANZ (2018) Safety, technical and health effects assessment – Application A1155 2'-FL and LNnT in infant formula and other products; 3. Puccio, G. et al. JPN 2017; 64: 624–631; 4. Berger, B. et al. 2020; 11(2): e03196-19 5. Gold et al. 2022 Nutrients May 30;14(11):229 6. Vandenplas et al. 2022. Nutrients. Jan 26;14(3):530

IMPORTANT NOTICE: Breast milk is best for babies and provides ideal nutrition. Good maternal nutrition is important for the preparation and maintenance of breastfeeding. Introducing partial bottle feeding could negatively affect breastfeeding and reversing a decision not to breastfeed is difficult. Professional advice should be followed on infant feeding. Infant formula should be prepared and used exactly as directed or it could pose a health hazard. The preparation requirements and weekly cost of providing infant formula until 12 months of age should be considered before making a decision to formula feed. Mothers should be encouraged to continue breastfeeding even when their infants have cow's milk protein allergy. If a decision to use an infant formula for special dietary use is taken, it must be used under medical supervision.

Nestlé Australia Ltd. 1 Homebush Bay Drive RHODES. ABN 77 000 011 316. ®Reg. Trademark of Societe des Produits Nestlé